E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Relapsed Refractory Mantle Cell Lymphoma |
|
E.1.1.1 | Medical condition in easily understood language |
Relapsed, refractory mantle cell lymphoma. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10026801 |
E.1.2 | Term | Mantle cell lymphoma refractory |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Estimate independently assessed progression free survival (PFS) in subjects with relapsed, refractory MCL. |
|
E.2.2 | Secondary objectives of the trial |
• Estimate Overall Survival.
• Estimate objective response rate, independently and investigator assessed.
• Estimate investigator assessed PFS.
• Assess safety, including adverse events of infection and bleeding.
• Quantify the potential effect of TEMSR to alter the disposition of desipramine, a substrate of CYP2D6 metabolism. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
The subject must meet all of the following criteria to be enrolled in the study:
1. MCL confirmed locally with histology, immunophenotype, and cyclin D1 analysis.
2. Male or female subjects aged 18 years or older.
3. Refractory to or relapsed from 2 to 7 prior therapies, which may include HSCT (ie, induction + consolidation + maintenance).
4. Prior treatment with an alkylating agent and an anthracycline and rituximab, individually or in combination.
5. Measurable disease in an area of no prior radiotherapy or clear progression in an area that was previously irradiated
6. Adequate organ and marrow function obtained within 2 weeks prior to first dose administration of TEMSR as defined by the following:
• Absolute neutrophil count (ANC) ≥ 1,000/μL
• Platelet (PLT) ≥75,000/μL (≥ 50,000/μL is allowed if with bone marrow involvement)
• Hemoglobin ≥ 8 g/dL
• Total bilirubin ≤ 1.5 x upper limit normal (ULN) (if abnormal, direct bilirubin must be ≤ 1.5 x ULN)
• Aspartate aminotransferase (AST) ≤ 3 x ULN (≤ 5 x ULN is allowed if with liver involvement)
• Serum creatinine ≤ 2 x ULN
• Fasting serum cholesterol ≤ 350 mg/dL (9.01 mmol/L)
• Triglycerides ≤ 400 mg/dL (4.5 mmol/L)
• Glycosylated hemoglobin (Hgb A1c) <10% (optimal therapy permitted)
• Other laboratory values all common toxicity criteria (CTC) version 3.0 grade ≤ 2 unless related to lymphomatous organ involvement.
7. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.
8. For women of child bearing potential, a negative serum pregnancy test prior to first dose administration of any investigational agen (ie: Desipramine and/or TEMSR). Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28 days after the last dose of assigned treatment. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
|
|
E.4 | Principal exclusion criteria |
Presence of any of the following criteria will exclude the subject from enrollment in the study:
1. Subjects who are ≤ 6 months from allogeneic HSCT and who are on immunosuppressive therapy or have evidence of graft host disease.
2. Prior investigational therapy within 3 weeks before first infusion of TEMSR. Investigational therapy is defined as treatment that is not approved for any indication.
3. Treatment within the following time frame relative to first dose administration of TEMSR:
• Chemotherapy, radiotherapy, immunotherapy, or major surgery ≤ 3 weeks
• Nitrosourea or mitomycin ≤ 6 weeks
• Radioimmunotherapy ≤ 8 weeks
• Other nonmyelosuppressive biological response modifiers < 2 weeks.
4. Active central nervous system (CNS) metastases. Subjects with brain metastases are eligible as long as they are clinically stable prior to first dose administration of TEMSR (no significant changes in anticonvulsant doses, mental status,or clinical symptoms related to CNS metastases) after completion of definitive therapy.
5. Current active second malignancy other than nonmelanoma skin cancers and clinically localized prostate cancer. Subjects are not considered to have a currently active malignancy if they have completed anti-cancer therapy with curative intent and are disease-free at least 2 years prior to first dose administration of TEMSR. Subjects with a history of cervical carcinoma in situ, breast ductal carcinoma in situ, or breast lobular carcinoma in situ are considered eligible provided they have completed definitive therapy.
6. Any prior history of noninfectious interstitial pneumonitis / interstitial lung disease.
7. Subjects who are receiving desipramine or have an intolerance to desipramine or other tricyclic antidepressants. (this criterion pertains only to subjects who are participating in the desipramine/PK sub-study)
8. Prior treatment with TEMSR or other mTOR inhibitor.
9. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality or cardiac dysfunction that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
10. Previous history of hypersensitivity to TEMSR, its metabolites (including sirolimus), polysorbate 80, or any other components of TEMSR formulation.
11. Hypersensitivity to antihistimines or subjects who cannot receive antihistimines for other medical reasons. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression free survival (PFS) based on blinded, independent tumor assessments will be the primary endpoint of this study. PFS is defined as the time from randomization to progressive disease or death. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Independentally assessed Progression Free Survival (PFS). Tumor assessments every 6-12 wks. Primary analysis approx. 69 PFS events. |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints include PFS per the investigator assessment and ORR per independent assessment. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Overall survival, objective response rate, investigator assessed PFS, and safety (including AE's of infection and bleeding), affect of TEMSR to alter the disposition of Desipramine. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Drug interaction with desipramine |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Temsirolimus lower dosage arm (75 mg IV weekly regimen) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Information not present in EudraCT |
E.8.4 | The trial involves multiple sites in the Member State concerned | Information not present in EudraCT |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 41 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Bulgaria |
Czech Republic |
France |
Germany |
Hong Kong |
Hungary |
India |
Italy |
Korea, Republic of |
Netherlands |
Poland |
Romania |
Russian Federation |
Serbia |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last Visit of the Last Patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |